Response to cellular stress represents a highly conserved pathway in evolution. Cells respond to stress with modified synthesis of new proteins by the formation of stress granules (SGs), inhibition of translation initiation and by increased recycling of cellular components through autophagy. One of the master regulators of this response is the mechanistic target of rapamycin (mTOR) kinase 1,2 . We recently reported that Staufen1 (STAU1), a stress granule protein, was overabundant in the rare neurodegenerative disorder SCA2 and provided a link between SG formation and autophagy 3 . In cells harboring mutant ATXN2, STAU1 could also be increased by bafilomycin A consistent with impaired autophagosome lysosome fusion 3 . Here we now examine this association and show the molecular mechanism leading to autophagic block in cells with microtubule associated protein tau (MAPT), presenilin 1 (PSEN1), huntingtin (HTT), TAR DNA-binding protein-43 gene (TARDBP) or C9orf72-SMCR8 complex subunit (C9orf72) mutations underlying a great number of neurodegenerative diseases 4-8 . We found that STAU1 overabundance was present in all cell lines and animal models tested, that it was posttranslational, and that it was associated with an increase in phosphorylated mTOR (P-mTOR) and autophagic block. Exogenous expression of STAU1 in wild-type cells was sufficient to reduce autophagic flux by itself. Mechanistically, STAU1 directly interacted with the mTOR-5'UTR and enhanced mTOR translation. As STAU1 itself is degraded by autophagy, this interaction and the resulting autophagic block results in a maladaptive amplifying response to chronic stress. Targeting STAU1 by RNAi decreased mTOR hyperactivity and normalized mTOR downstream targets in dividing cells, post-mitotic neurons and animal models of SCA2 and ALS-TDP-43 or C9orf72 associated neurodegeneration. In summary, STAU1 is necessary and sufficient to mediate a maladaptive cellular stress response and is a novel target for RNAimediated treatment of neurodegenerative diseases.
Introduction
Staufen was identified in the fly as a protein determining the spatiotemporal localization of maternal mRNAs in oocytes and eggs [9] [10] [11] . Mammals have two Staufen proteins (STAU1 and STAU2), both involved in mRNA localization and transport [11] [12] [13] [14] [15] [16] . Binding of STAU1 to the 3'UTRs of specific classes of RNAs leads to Staufen-mediated decay (SMD) whereas binding to the 5'UTR results in enhanced translation [16] [17] [18] [19] .
We previously showed that STAU1 was part of the ATXN2 protein complex and that fibroblasts (FBs) from individuals with SCA2 or TDP-43 G298S mutations had elevated STAU1 levels 3 . When STAU1 expression was reduced by genetic interaction, motor behavior of SCA2 mice improved with normalization of key Purkinje cell proteins and reduction of cytoplasmic aggregates containing ATXN2 (ref. 3) . We found that a large number of differentially regulated genes in our SCA2 model overlapped with RNAs identified by crosslinking with STAU1(ref. 20) and demonstrated a direct interaction of the PCP2-3'UTR with STAU1 (ref. 3 ).
Results and Discussion

STAU1 overabundance is common in cell lines derived from patients with neurodegenerative diseases
We now explored whether STAU1 overabundance was represented a more generalized response of cells stressed by presence of mutant disease proteins or other chronic stressors.
We therefore obtained FBs from ALS patients with a variety of TDP-43 mutations or with repeat expansion in C9orf72, HD patients with huntingtin (HTT) poly-Q expansion and Alzheimer's disease patients with PSEN1 or MAPT mutations. By quantitative western blot analysis, STAU1 was significantly increased in all patient cell lines ( Fig. 1a-e ). The STAU1 mRNA levels, however, were unchanged (Extended Data Fig. 1a,b ).
Stau1 overabundance is associated with autophagy dysfunction
In prior studies, we had found that STAU1 was primarily degraded through the autophagosome, presumably owing to its association with RNA granules. We therefore tested whether autophagy was impaired in cells with endogenously elevated STAU1 and whether exogenous expression of mutant disease-linked proteins could result in STAU1 overabundance and impaired autophagy.
A master regulator of autophagy is mTOR and once phosphorylated (P-mTOR), it serves as a kinase of several targets including ribosomal protein S6 kinase (S6K1), and eukaryotic initiation factor 4E-binding protein (4E-BP1). FBs obtained from SCA2 patients all showed an increase in total mTOR and active P-mTOR levels, and an increase in p62 and LC3-II levels indicating reduced autophagic flux ( Fig. 1e) . Activation of mTOR was also evident in cells from patients with ALS, HD and AD ( Fig. 1a-d) . Increased STAU1 and mTOR levels in these FBs were not the result of transcriptional changes (Extended Data Fig. 1a,b) .
It is possible that patient-derived cells may contain other unknown mutations in addition to the respective causative mendelian mutation. We therefore used two independent approaches to establish a causative relationship from disease proteins to STAU1 overabundance to autophagosome dysfunction. First, we modified HEK-293 cells using the CRISPR/Cas9 system to introduce disease-causing mutations. When compared to wild-type HEK-293 cells, cells with endogenous mutated ATXN2, designated ATXN2-Q22/58 KI (ref. 3) showed increased STAU1, mTOR and P-mTOR levels. As expected in the presence of overabundant P-mTOR, downstream effectors of mTOR signaling showed increased abundance and phosphorylation as well (P-S6 and P-4E-BP1) (Extended Data Fig. 2a ).
Second, we expressed disease causing proteins exogenously in HEK-293 cells to determine whether they recapitulated STAU1 overabundance and mTOR activation. This included wild-type or mutant TDP-43 (G298S, A382T and G348C), C-terminal fragment (CTF) of TDP-43 and MAPT mutation 4, 7, 21 . Exogenous expression of disease-linked proteins resulted in increased mTOR activities (Extended Data Fig. 2b-d) . These results support that presence of mutant disease-linked proteins are directly related to STAU1 overabundance and autophagy impairment.
Stau1 is overabundant in mouse models of neurodegeneration
Although STAU1 overabundance and impaired autophagy were seen in a number of cell lines from patients with various neurodegenerative conditions, this analysis used cells that are actively dividing. To examine STAU1 levels in post-mitotic neurons in vivo we analyzed brain protein extracts from a number of mouse models expressing human mutant proteins. As previously reported, STAU1 is overabundant in cerebellar extracts of SCA2 mice 3, 22, 23 . We now examined the state of autophagy in these mice and find that the in vivo results mirrored the ones obtained using SCA2 cell lines ( Fig. 2a) .
We then extended this analysis to a mouse line expressing wild-type TDP-43 (refs. 24-26) and a mouse line expressing a human BAC with mutant C9orf72 repeat 27 . By western blot analysis, both TDP-43 Tg/+ hemizygous and BAC-C9orf72 mice demonstrated greatly increased Stau1 levels similar to those seen in ATXN2 Q127 mice ( Fig. 2b-d) . Associated with elevated Stau1, we found that autophagy pathway components were altered predicting reduced flux by inefficient autophagosome-lysosome fusion. This included total and phosphorylated mTor as well as p62 and LC3-II which functions as a selective autophagy receptor for degradation of ubiquitinated substrates ( Fig. 2a-d ).
STAU1 directly interacts with the 5'UTR of mTOR and enhances its translation
We determined if exogenous expression of STAU1 in HEK-293 cells resulted in the same alterations that were seen in cells with neurodegenerative disease-linked mutations. Expression of STAU1 resulted in increased mTOR, P-mTOR, p62 and LC3-II levels (Fig. 3a) . Levels of mTOR transcripts were unchanged (Fig. 3b) . These results indicated that STAU1 overabundance was sufficient to induce autophagic dysfunction.
As STAU1 can enhance translation of mRNAs upon binding to 5'UTRs (ref. 17) , we tested whether STAU1 was able to bind mTOR RNA and whether this interaction would increase translation of mTOR mRNA. We used two independent approaches to establish an interaction between STAU1 and mTOR RNA. First, Protein-RNA immunoprecipitation (non-RNase A treated) followed by RT-PCR in HEK-293 cells expressing Flag-tagged STAU1 demonstrated that Flag-STAU1 pulled down mTOR mRNA but not control GAPDH (Fig. 3c) . Second, using bacterially expressed recombinant His-tagged STAU1 protein and in vitro transcribed DIGlabelled mTOR RNA probes, we were able to map the interaction of STAU1 to the mTOR-5'UTR by northwestern blot analysis ( Fig. 3d,e ).
To test the consequence of STAU1 binding to the mTOR RNA, we inserted the mTOR-5'UTR upstream of luciferase. In the presence of exogenous STAU1, translation was greatly increased ( Fig. 3f-h) . We tested for the specificity of STAU1 interaction with the UTR sequence by substituting the mTOR-5'UTR with the PCP2-5'UTR as PCP2 is known only to be subjected to SMD not mediated by its 5'UTR (ref. 3) . Exogenous STAU1 resulted in significant induction of luciferase activity only from mTOR-5'UTR-LUC construct ( Fig. 3f-h) . The double stranded RNA binding domain 3 (dsRBD3) of STAU1 acts as the major functional domain for target RNA interactions [28] [29] [30] . The translational increase was dependent on the presence of this domain as its deletion abrogated the effect of STAU1 on translation ( Fig. 3i-k) . These data explain mTOR increase and map the interaction to the 5'UTR of the mTOR RNA and the dsRBD3 domain of STAU1.
STAU1 responds to a variety of stressors
Accumulating evidence indicates that stress-induced intracellular changes lead to neurotoxicity in a number of neurodegenerative diseases [31] [32] [33] [34] . We wanted to test whether subjecting cells to various forms of stress other than expression of disease-linked genes would affect STAU1 and autophagic function. We used HEK-293 cells and subjected them to endoplasmic reticulum (ER) stressors (thapsigargin or tunicamycin), a calcium ionophore (ionomycin), oxidative stress (tunicamycin), metal stressor (sodium arsenite) and temperature stress (hyperthermia) followed by western blotting. The different forms of stress all induced STAU1 overabundance, mTOR elevation and increased phosphorylation of mTOR targets (Fig 4a-e ). To confirm the involvement of STAU1 in the activation of this pathway we established primary cultures of cortical neurons from wild-type and Stau1 -/mice. For wild-type neurons, treatments with thapsigargin induced Stau1 overabundance and mTor activation with increased p62 and LC3-II levels. In contrast, Stau1 -/neurons showed minimal response to thapsigargin ( Fig. 4f) ,
indicating that the activation of mTOR and downstream targets is STAU1 dependent. Although the precise signaling pathways are not yet known, these findings indicate that STAU1 is positioned at the crossroads of several cellular stress pathways.
Reduction of overabundant STAU1 normalizes autophagy
Exogenous STAU1 expression was sufficient to change autophagic flux, shown above. We now needed to determine whether STAU1 was necessary. To test this, we knocked STAU1 down in the presence of mutant disease proteins in vitro and in vivo. When we depleted STAU1 in ATXN2-Q58 KI cells by STAU1 RNAi, mTOR levels were normalized. Reduced mTOR activity was verified by reduced P-mTOR, P-S6 and P-4EBP1 levels, and restoration of p62 and LC3-II turnover (Fig. 5a ). Thus, reducing STAU1 levels was sufficient in rescuing autophagic flux in SCA2 cells.
We next proceeded to determine if lowering STAU1 levels could restore autophagic flux in ALS cellular models. Like in ATXN2-KI cells, lowering STAU1 levels by RNAi in ALS-TDP-43 or C9orf72 cell models also restored autophagic flux (Fig. 5b,c) . Of note, silencing of STAU1 had no effect on TDP-43 protein levels. These data indicate that STAU1 knockdown may be useful for preventing maladaptive responses to cellular stress.
Since lowering STAU1 levels can normalize aberrant autophagy associated with SCA2, TDP-43 and C9orf72 mutations, we wanted to test if reducing STAU1 levels is protective of pathological stress. We treated HEK-293 cells with STAU1 RNAi followed by wild-type or mutant TDP-43 transfection. In all cases, lowering STAU1 normalized mTOR signaling and autophagy (Extended Data Fig. 3) . These results establish that STAU1 plays a key role in protecting cells from a wide variety of pathological stressors.
In vivo results
The availability of a mouse with a Stau1 loss-of-function allele allowed us to determine the effect of Stau1 reduction using genetic interaction. We crossed SCA2 or TDP-43 mouse lines with Stau1 KO mice generating animals that had 50% or 0% Stau1 protein levels 3, 22, 24, 35 .
We had previously observed that reduction of Stau1 in vivo improved motor behavior and proteomics in SCA2 mice 3 . We then measured mTor, P-mTor, p62, and LC3-II to determine autophagic flux. Changing Stau1 dosage in wild-type animals did not alter autophagy marker proteins in an appreciable way. In contrast, reducing pathologically elevated Stau1 in SCA2 mice improved markers of autophagy in a dose-dependent fashion such that levels of all proteins were returned to near normal ( Fig. 6a,b,d ). Similar to in SCA2 mice, reducing Stau1 dosage by 50% in TDP-43 Tg/+ mice resulted in decreased mTOR activity and restoration of autophagy pathway proteins ( Fig. 6c,e ).
Our results have implications for the basic understanding of mechanisms regulating autophagy and for identifying novel targets for the treatment of neurodegeneration. Current understanding of autophagy emphasizes regulation by kinase cascades and by transcriptional changes in key genes involved in autophagy [36] [37] [38] [39] . We now describe an additional regulatory mechanism that involves RNA-binding proteins, formation of SGs with the ability of acutely influencing the translation of already transcribed mRNAs. The double-stranded RNA-binding protein STAU1 directly interacts with mTOR-mRNA and enhances its translation. As STAU1 is itself degraded by autophagy, this establishes an amplification mechanism for autophagy inhibition.
STAU1 is also a key player in RNA decay, and its overabundance likely affects RNA networks that involve cellular functions and signaling cascades in addition to autophagy. Little is known about these networks in individual cell types other than HEK-293 cells 3 , but it is reasonable to assume that some of the cell-type specificity in neurodegenerative diseases is mediated via RNA decay. It is tempting to speculate that overabundance of STAU1 also provides a bridge from RNA granule formation to aberrant phase transition to hydrogels, a mechanism important in several neurodegenerative diseases 40 .
In summary, we found that STAU1 is highly overabundant in multiple cellular and mouse models of neurodegenerative disease and that targeting STAU1 could restore abnormal downstream signaling to autophagy. STAU1 may be an outstanding novel target for antisense oligonucleotide (ASO)-or RNAi-based therapies. Our past studies in an SCA2 mouse model showed that reducing STAU1 by only 50% improved motor behavior 3 . We now show that this improvement is associated with restoration of P-mTOR levels and downstream targets of mTOR-kinase in vivo. For C9orf72 neurodegeneration, targeting STAU1 may provide a better or additional target as the C9orf72 gene product appears to have essential cellular functions. As compared with other approaches to improving autophagy, targeting STAU1 may have the added advantage of normalizing SMD as well. 
Supplementary Table 1. RT-PCR and qRT-PCR primer sequences
GAPDH-F 5'-ACATCGCTCAGACACCATG-3' Human RT-PCR GAPDH-R 5'-TGTAGTTGAGGTCAATGAAGGG-3' " " mTOR-F 5'-CGAACCTCAGGGCAAGATG-3' " " mTOR-R 5'-TTTCCTCATTCCGGCTCTTTAG-3' " " ACTB-F 5'-GAAAATCTGGCACCACACCT-3' " qRT-PCR ACTB-R 5'-TAGCACAGCCTGGATAGCAA-3' " " mTOR-F 5'-CAGAAGGTGGAGGTGTTTGAG-3' " " mTOR-R 5'-TGACATGACCGCTAAAGAACG-3' " " Stau1-F 5'-AGTACATGCTCCTTACAGAACG-3' Mouse " Stau1-R 5'-TGATGCCCAACCTTTACCTG-3' " " mTor-F 5'-ATTCAATCCATAGCCCCGTC-3' " " mTor-R 5'-TGCATCACTCGTTCATCCTG-3' " " Actb-F 5'-CGTCGACAACGGCTCCGGCATG-3' " " Actb-R 5'-GGGCCTCGTCACCCACATAGGAG-3' " "
Supplementary Information
Staufen blocks autophagy in neurodegeneration
Methods
DNA constructs
The plasmid constructs used in this study were 3XFlag-tagged STAU1 or wild-type TDP-43, His- 
Cell culture and Transfections
Five SCA2 patient-derived skin FBs (ATXN2 with CAG repeats; 35, 35 
Cell line authentication
We authenticated cell lines used in the study (as HEK-293 cells or human fibroblasts, etc) by short tandem repeat (STR) analysis, an approach that evaluates 24 loci including Amelogenin for sex identification, using the GenePrint 24 System (Promega, USA). We also used PCR sequencing to verify the presence of mutations in patient-derived cells. This is in part in response to NIH guidelines on scientific rigor in conducting biomedical research (NOT-OD-15-103). 
Mice
Antibodies
The antibodies used for western blotting and their dilutions were as follows: mouse anti-Ataxin-2 images were scanned and band intensities were quantified by ImageJ software analyses after inversion of the images, and the relative protein abundances were expressed as ratios to β-Actin. In vitro RNA binding (Northwestern) assays were performed to determine STAU1 and mTOR-5'UTR interaction using our previously published protocol 3 .
Preparation of protein lysates, western blotting and in vitro RNA binding assays
Immunoprecipitations
To determine protein-RNA interactions, we carried out protein-RNA immunoprecipitation (IP) experiments using HEK-293 cells expressing Flag-STAU1. The preparation of whole cell extracts and IP methods followed previously published methods 3 the NaCl concentration was adjusted to physiologic buffer conditions (~150 mM) to preserve in vivo interactions. Ninety percent of cell extracts were subjected to Flag monoclonal antibody (mAb) IP (Anti-FlagM2 Affinity Gel, Sigma-Aldrich, A2220-1ML) to immunoprecipitate STAU1
interacting protein-RNA complexes. The remaining 10% of whole cell extracts were saved as the input control for western blotting and RT-PCR analyses. The IPs were washed with a buffer containing 200 mM NaCl and the bound protein-RNA complexes were eluted from the beads with Flag peptide competition (100 μg/ml) (Flag Peptide, Sigma-Aldrich, F3290-4MG). Eluted fractions were divided into two equal parts. One part was analyzed by SDS-PAGE followed by western blotting to determine STAU1 expression. RNA was isolated from the other fraction and subjected to RT-PCR analyses to identify RNAs that bound to STAU1.
RNA expression analyses by quantitative RT-PCR
Mice were deeply anesthetized with isoflurane then decapitated. Mouse cerebella or spinal cord were removed and immediately submerged in liquid nitrogen. Tissues were kept at −80°C until the time of processing. Total RNA was extracted from mouse tissues and harvested cells using the RNeasy Mini-Kit according to the manufacturer's protocol (Qiagen, USA). DNAse I treated RNAs were used to synthesize cDNAs using the ProtoScript cDNA synthesis kit (New England Biolabs, USA). Quantitative RT-PCR was performed in QuantStudio 12K (Life Technologies, USA) with the Power SYBR Green PCRMaster Mix (Applied Biosystems, USA) using University of Utah genomics core lab. PCR reaction mixtures contained SYBR Green PCRMaster mix, synthesized cDNA and 0.5 pmol primers, and PCR amplifications were carried out for 45 cycles: denaturation at 95°C for 10 sec, annealing at 60°C for 10 sec and extension at 72°C for 40 sec.
The threshold cycle for each sample was chosen from the linear range and converted to a starting quantity by interpolation from a standard curve run on the same plate for each set of primers. Commercial TaqMan assay (Cat# 4331182: Hs00244999_m1 for STAU1 probe and Hs01060665_g1 for ACTB probe, ThermoFisher Scientific) was used to detect STAU1. All gene expression levels were normalized to ACTB or GAPDH or Actb mRNA levels. Primer pairs designed for RT-PCR and qRT-PCR are given as forward and reverse, respectively, and listed
in Supplementary Table 1 .
Statistical analysis
